Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The connection between M. morganii, inflammation, and depression aligns with earlier research. IL-6 has been repeatedly ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Also in the news, "renal denervation" shows promise as a treatment for high blood pressure; an estimated 17 million U.S. adults struggle with long-covid with no new treatments in sight; inequality ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...